More counterfeit Botox has made its way into the U.S. and, the FDA thinks, into physician offices. The agency is warning providers that they need to make sure they don't have any of it because it is believed to be unsafe.
The FDA said it's stepping up its efforts to address the shortage of saline solution for humans and animals by increasing the importation of intravenous fluids from producers not previously approved by the regulatory agency.
Walgreens Boots Alliance has been so pleased with its relationship with AmerisourceBergen that it might just look for another drug distributor with which to hook up. That was the suggestion made by Walgreens CEO Stefano Pessina this week.
Pharma puts so much emphasis on top line that drugmakers give scant consideration to what their supply chains are costing them. But a new report suggests that making a supply chain more efficient is not only going to save costs, but it will also help drive greater sales.
A Canadian drug distributor began recalling a small quantity of Pfizer birth control pills this week after it accidentally shipped out expired product. Pfizer credited the company with quick action, but it is the kind of issue that in the past has led to litigation against drugmakers over unwanted pregnancies.
Drugs can end up on the FDA shortage list for many reasons, with manufacturing problems and recalls often being the culprit. But a new report says that for more than a decade, poor management by the Drug Enforcement Agency and a touchy relationship between the DEA and FDA have been at the heart of many shortages of controlled substances.
The decision by Irish drugmaker Alkermes to narrow its focus and sell a manufacturing plant is providing a chance for Pennsylvania-based Recro Pharma to expand its pain drug position and jump into the the contract manufacturing space to pick up some extra cash.
Several factors in the manufacturing process can lead to a drug shortage. Now, the FDA has launched an effort to combat the effects of such shortages, bringing the battle to your smartphone.
Hospitals continue to pressure Roche's Genentech to stop using specialty distributors for some of its cancer meds. The latest move is a survey in which not only do respondents claim the change is costing them money, but more than a quarter said it is delaying patient care, The Wall Street Journal blog Pharmalot reports.
The ability of Maine consumers to get cheaper drugs from across the Canadian border has been on-again and off-again. Now it is off again.